TRVI Stock Recent News

NEW HAVEN, Conn. , May 29, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc.  (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in June.

Results of analyses presented at an investor meeting during the American Thoracic Society 2025 International Conference NEW HAVEN, Conn. , May 20, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced additional analyses from the Phase 2a RIVER trial of Haduvio for the treatment of patients with RCC (N=66).

The mean of analysts' price targets for Trevi Therapeutics (TRVI) points to a 195.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Jennifer Good - Co-Founder, President and Chief Executive Officer Lisa Delfini - Chief Financial Officer James Cassella - Chief Development Officer Farrell Simon - Chief Commercial Officer Conference Call Participants Faisal Khurshid - Leerink Annabel Samimy - Stifel Leland Gershell - Oppenheimer Deepa Njama - Jones Trading Mayank Mamtani - B. Riley Securities Kaveri Pohlman - Clear Street Operator Good afternoon and welcome to the Trevi Therapeutics First Quarter 2025 Earnings Conference Call.

Completed enrollment and last patient last visit in the Phase 2b CORAL trial in IPF patients with chronic cough; topline results continue to be expected in the second quarter of 2025 Announced positive topline results from the Phase 2a RIVER trial in patients with refractory chronic cough Management to host a conference call and webcast today at 4:30 p.m. ET  NEW HAVEN, Conn.

Conference call and webcast to be held at 4:30 p.m. ET   NEW HAVEN, Conn.

NEW HAVEN, Conn. , April 3, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be participating in the following investor conferences in April.

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Jennifer Good - Co-Founder, President and Chief Executive Officer Lisa Delfini - Chief Financial Officer Conference Call Participants Faisal Khurshid - Leerink Partners Mayank Mamtani - B. Riley Annabel Samimy - Stifel Leland Gershell - Oppenheimer Serge Belanger - Needham & Company Ryan Deschner - Raymond James Brandon Folkes - Rodman & Renshaw Christian Cubides - Clear Street Operator Good afternoon and welcome to the Trevi Therapeutics Fourth Quarter and Year End 2024 Earnings Conference Call.

Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough (RCC), making Haduvio the first therapy in clinical development to show benefit in patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and RCC Completed enrollment in the Phase 2b CORAL trial in IPF patients with chronic cough in February 2025, with topline data expected in the second quarter of 2025 Announced positive outcome from sample size re-estimation in the Phase 2b CORAL trial, resulting in no change to study sample size Ended 2024 with $107.6 million in cash, cash equivalents and marketable securities, with expected cash runway into the second half of 2026 Management to host a conference call and webcast today at 4:30 p.m. ET  NEW HAVEN, Conn.

Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn.